Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion OyjORINF 97 Debt-to-EBITDA is 0.19 as of Jun. 2026, which is 57% below its 10-year median of 0.44. GuruFocus rates ORINF with a GF Score™ of 97/100 and a GF Value™ of $80.70. The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Orion Oyj ranks better than 73.33% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orion Oyj's Debt-to-EBITDA or its related term are showing as below:
ORINF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.44 Max: 0.64
Current: 0.18
During the past 13 years, the highest Debt-to-EBITDA Ratio of Orion Oyj was 0.64. The lowest was 0.03. And the median was 0.44.
ORINF's Debt-to-EBITDA is ranked better than 73.33% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs ORINF: 0.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Orion Oyj Debt-to-EBITDA Related Terms
Orion Oyj Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Orion Oyj (ORINF) has a Debt-to-EBITDA of 0.19 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Oyj. This is 57% below median its historical median of 0.44. Over the past decade, Orion Oyj's Debt-to-EBITDA has ranged from 0.03 to 0.64. According to the industry distribution chart, Orion Oyj ranks #184 out of 690 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Orion Oyj's Debt-to-EBITDA too high?
Orion Oyj's current Debt-to-EBITDA of 0.19 is 57% below median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.64. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Orion Oyj's value of 0.19 is 88.6% below this industry median. Based on the distribution chart, Orion Oyj ranks #184 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #184 out of 690 companies for Debt-to-EBITDA. This puts Orion Oyj in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Orion Oyj's value of 0.19 is 88.6% below this benchmark. Historically, Orion Oyj's own Debt-to-EBITDA has ranged from 0.03 to 0.64 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 1.67, Orion Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Debt-to-EBITDA of 0.19 is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Oyj. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Debt-to-EBITDA is 0.19, which is 57% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Debt-to-EBITDA of 0.19. The stock's GF Value™ is $80.70, compared to a current price of $82.75 — trading 2.5% above its estimated fair value. The current Debt-to-EBITDA is 0.19, which is 57% below median its 10-year median of 0.44 and 88.6% below the Drug Manufacturers industry median of 1.67. Orion Oyj's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Debt-to-EBITDA is 0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.5% above its estimated GF Value™ of $80.70.
Key valuation signals for ORINF:
Debt-to-EBITDA: 0.19 (57% below median its 10-year median of 0.44)
GF Value™: $80.70 vs. price of $82.75 (2.5% above fair value)
Industry Position: 88.6% below the Drug Manufacturers median (#184 of 690)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
